Comparative Effectiveness of Biologic Agents among Black and White Medicare Patients in the US with Metastatic Colorectal Cancer

Medicine & Life Sciences

• Biological Factors 100%
• Medicare 96%
• Colorectal Neoplasms 74%
• African Continental Ancestry Group 23%
• Drug Therapy 22%
• European Continental Ancestry Group 21%
• Survival 20%
• Biological Products 13%
• ramucirumab 7%
• Epidemiology 7%
• Comparative Effectiveness Research 7%
• Panitumumab 6%
• aflibercept 6%
• Cohort Studies 6%
• Capecitabine 5%
• Cetuximab 5%
• Databases 5%
• Biological Therapy 5%
• Oxaliplatin 5%
• Irinotecan 5%
• Population 5%
• Bevacizumab 5%
• Fluorouracil 4%
• Proportional Hazards Models 4%
• Colon 3%
• Randomized Controlled Trials 3%
• Health Care Outcome Assessment 3%
• Mortality 2%
• Therapeutics 1%